相关实验视频

Updated: Jul 11, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

布鲁顿的氨酸激酶是微观多炎的可能治疗点

Issei Nakade¹, Yuto Tamura¹, Fuyu Hashimoto¹

¹Department of Medical Laboratory Science, Faculty of Health Sciences, Hokkaido University, Kita-12, Nishi-5, Kita-Ku, Sapporo, 0600812, Japan.

Arthritis research & therapy

|November 7, 2023

概括

布鲁顿的氨酸激酶 (Btk) 抑制剂tirabrutinib减少了中性粒细胞外陷 (NETs) 和改善了实验性微观多炎 (MPA) 在老鼠. 这表明Btk是MPA的潜在治疗点,因为它针对NET形成.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
类风湿病学类风湿病学

背景情况:

布鲁顿的氨酸激酶 (Btk) 对于B细胞受体和Fcγ受体信号传递至关重要.
抑制Btk可能会降低自身抗体的产生和FcγR介导的中性粒细胞激活,包括NET释放.
微观多炎 (MPA) 病原发生涉及髓氧化酶 (MPO) - 抗核素细胞质抗体 (ANCA) 复合体诱导的NETs.

研究的目的:

评估Btk抑制剂tirabrutinib在实验性微观多炎 (MPA) 的治疗疗效.

主要方法:

提布鲁丁尼布被给予大鼠,以评估Btk酸化和B淋巴细胞计数.
人类中性粒细胞被MPO-ANCA免疫复合体 (IC) 刺激,以评估Btk激活和NET形成在体外.
在老鼠中诱导实验MPA,并评估了tirabrutinib对疾病进展,自身抗体标位和NET形成的影响.

主要成果:

特拉布鲁丁尼抑制了Btk酸化,但没有影响体内B淋巴细胞数量.
在中性粒细胞中,MPO-ANCA ICs诱导了Btk和Vav酸化,这种酸化被tirabrutinib抑制,在体外减少了NET的形成.
提拉布鲁替尼通过减少NET形成的中性粒细胞而以剂量依赖的方式改善实验MPA,而不会影响MPO-ANCA标位.

结论:

提拉布鲁替尼有效抑制MPO-ANCA IC诱导的NET形成,并改善了实验MPA.
治疗效果归因于减少NET形成的中性粒细胞,而不是MPO-ANCA标位.
布鲁顿的氨酸激酶 (Btk) 是微观多炎 (MPA) 的一个有前途的治疗点.

关键词:

Btk 的意思是这是一种Btk抑制剂.这是一个MPA,MPA是MPA.在MPO-ANCA中,我们可以看到MPO-ANCA.网络网络网络网络提拉布鲁丁尼布的使用情况

更多相关视频

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...